Cancer research groups partner for liquid biopsy trial

By The Science Advisory Board staff writers

July 30, 2020 -- The Cancer Research Institute and the Mark Foundation for Cancer Research have partnered on a clinical trial to evaluate whether a novel liquid biopsy diagnostic can assess immune response in cancer patients.

In a phase II, multicenter trial, researchers from the Canadian Cancer Trial Group will first investigate whether changes in circulating cell-free tumor DNA (ctDNA) can better predict immunotherapy response than radiographic assessments. They will then examine whether ctDNA patterns can guide treatment decisions for patients with non-small cell lung cancer.

The trial will be conducted at six sites in Canada and the U.S. and is expected to be completed in December 2021. It is being chaired by Dr. Valsamo Anagnostou, PhD, an assistant professor of oncology at Johns Hopkins whose previous research has demonstrated that ctCNA levels can predict clinical response.


Copyright © 2020 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?